TCD601

Phase 2Biologic

IITB-Med LLC

TCD601 is one of 47 biologic programs targeting Liver Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Renal Transplant RecipientsActive, not recruiting

Liver TransplantPhase 2

Active, not recruiting

Renal Transplant RecipientsPhase 2

Active, not recruiting

Competition

Competitive Landscape

95 competitors in Liver Transplant

#DrugCompanyPhaseTrials

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

1 2

Prothrombin Complex Concentrate

CSL Behring

Phase 3

1 3

Tacrolimus Pill

EEdward Geissler

Phase 3

1 4

Lenvima

Eisai

Preclinical

2 5

Octreotide

Johnson & Johnson

Preclinical

2 6

Beyfortus

BeiGene

Preclinical

1 7

Prostigmin

Merck & Co.

Preclinical

1 8

Myfortic

Novartis

Preclinical

1 9

Cyklokapron

JJ Molner

Preclinical

2 10

TCD601

IITB-Med LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Active, not recruiting

Liver Transplant

NCT06019507

Clinical

Trials by Indication[1]

De Novo Renal Transplantation2 trials

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Terminated·IITB-Med LLC·Phase 2·NCT06365437·33 enrolled

A Dose Escalation Study in de Novo Renal Transplantation

Completed·IITB-Med LLC·Phase 2·NCT04311632·13 enrolled

Kidney2 trials

An Adaptive, Regimen Finding, Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-myeloablative Conditioning, for Tolerance Induction in Living Donor Renal Transplantation

Terminated·IITB-Med LLC·Phase 2·NCT04803006·4 enrolled

A Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-Myeloablative Conditioning, Including Fludarabine and Cyclophosphamide, for Tolerance Induction in Living Donor Renal Transplantation

Terminated·IITB-Med LLC·Phase 2·NCT04803058·7 enrolled

Type 1 Diabetes1 trial

A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

Terminated·IITB-Med LLC·Phase 2·NCT06025110·9 enrolled

Liver Transplant1 trial

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Active, not recruiting·IITB-Med LLC·Phase 2·NCT06019507·12 enrolled

Renal Transplant Recipients1 trial

A Study of TCD601 in de Novo Renal Transplant Recipients

Active, not recruiting·IITB-Med LLC·Phase 2·NCT05669001·76 enrolled

1 more indication

ALS1 trial

A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Trial of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)

Terminated·IITB-Med LLC·Phase 1·NCT06453668·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for TCD601. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TCD601 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TCD601. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ITB-Med LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IITB-Med LLC

TCD601

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

De Novo Renal Transplantation2 trials

Kidney2 trials

Type 1 Diabetes1 trial

Liver Transplant1 trial

Renal Transplant Recipients1 trial

ALS1 trial

References

Drug Info

Quick Facts

Related News